Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Supportive Therapeutics AG is currently navigating 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action constitutes the entirety of the company's active prosecution as reflected in the current data. The workload is focused within 1 distinct art unit, which indicates a specialized technical area for the company's current patenting efforts.
The busiest examiner for this portfolio is SZNAIDMAN, MARCOS L, who is currently managing 1 pending office action. Because there is only 1 distinct examiner involved, this individual is responsible for all of the company's current pending matters. The concentration of 1 pending office action under 1 examiner and within 1 art unit creates a singular point of contact for the company's prosecution. Practitioners should note that the immediate outcome for the portfolio depends on the specific requirements and interpretations of this single examiner. This lack of diversification across examiners or art units for the 1 pending action means the company's strategy is highly dependent on a single examiner's review.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17946789 | Rotomeric Isomers of 4-Alkyl-5-Heteroaryl-3H-1,2-Dithiole-3-Thiones | SZNAIDMAN, MARCOS L | 79d |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17946789 | Rotomeric Isomers of 4-Alkyl-5-Heteroaryl-3H-1,2-Dithiole-3-Thiones | SZNAIDMAN, MARCOS L | 1628 | DPOther | Final Rejection | 79d | Pending | Sep 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial